Literature DB >> 26393501

Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively.

Nikolaos Charalampakis1, Lianchun Xiao, Elena Elimova, Roopma Wadhwa, Hironori Shiozaki, Yusuke Shimodaira, Mariela A Blum, Venkatram Planjery, Jane E Rogers, Aurelio Matamoros, Tara Sagebiel, Prajnan Das, Jeffrey H Lee, Manoop S Bhutani, Brian Weston, Jeannelyn S Estrella, Brian D Badgwell, Jaffer A Ajani.   

Abstract

BACKGROUND: In patients with localized gastric adenocarcinoma (LGAC) who receive preoperative therapy, tools to predict response or prognosticate outcome before therapy are lacking. We used initial standardized uptake value (iSUV) of positron emission tomography (PET) to evaluate its association with overall survival (OS).
METHODS: We identified 60 patients with confirmed LGAC who were treated with preoperative chemoradiation and had a baseline PET in addition to other routine staging. Fisher's exact test and Wilcoxon's rank sum test were used to determine the association between iSUV and other variables, and the log-rank test and Cox proportional hazards model were used for survival analysis.
RESULTS: The median iSUV was 6 (range, 0-28). The presence of signet ring cells in pretreatment biopsies correlated highly with low iSUV (≤ 6; p = 0.0017). Patients with a high iSUV (> 6) had a longer OS compared to those with a low iSUV (≤ 6; p = 0.0344). iSUV was not an independent predictor (p = 0.12); however, the risk of death was reduced for patients with an iSUV > 6 (hazard ratio = 0.26).
CONCLUSION: Our novel findings show that among LGAC patients treated with preoperative chemoradiation and surgery, those with a high iSUV have longer OS than patients with a low iSUV. iSUV appears to have a predictive role in patients with LGAC when treated with preoperative chemoradiation.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26393501      PMCID: PMC4659715          DOI: 10.1159/000436972

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  39 in total

1.  Therapy: localized gastric cancer--a CLASSIC shift in the paradigm?

Authors:  Mariela A Blum; Jaffer A Ajani
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-03-06       Impact factor: 46.802

2.  [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.

Authors:  D Vallböhmer; A H Hölscher; P M Schneider; M Schmidt; M Dietlein; E Bollschweiler; S Baldus; H Alakus; J Brabender; R Metzger; S P Mönig
Journal:  J Surg Oncol       Date:  2010-08-01       Impact factor: 3.454

3.  Over-expression of facilitative glucose transporter genes in human cancer.

Authors:  T Yamamoto; Y Seino; H Fukumoto; G Koh; H Yano; N Inagaki; Y Yamada; K Inoue; T Manabe; H Imura
Journal:  Biochem Biophys Res Commun       Date:  1990-07-16       Impact factor: 3.575

4.  Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography.

Authors:  Srikrishna V Patnana; Santosh B Murthy; Lianchun Xiao; Eric Rohren; Wayne L Hofstetter; Stephen G Swisher; Zhongxing Liao; Jeffrey H Lee; Manoop S Bhutani; Homer A Macapinlac; Xuemei Wang; Jaffer A Ajani
Journal:  Cancer       Date:  2010-10-01       Impact factor: 6.860

Review 5.  Role of glutamine in cancer: therapeutic and imaging implications.

Authors:  Kartik N Rajagopalan; Ralph J DeBerardinis
Journal:  J Nucl Med       Date:  2011-06-16       Impact factor: 10.057

6.  Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival.

Authors:  T Kawamura; T Kusakabe; T Sugino; K Watanabe; T Fukuda; A Nashimoto; K Honma; T Suzuki
Journal:  Cancer       Date:  2001-08-01       Impact factor: 6.860

7.  Role of ¹⁸F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection.

Authors:  Jeong Won Lee; Sang Mi Lee; Moon-Soo Lee; Hyeong Cheol Shin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-07       Impact factor: 9.236

8.  Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract.

Authors:  Ji-Youn Sung; Gou Young Kim; Sung-Jig Lim; Yong-Koo Park; Youn Wha Kim
Journal:  Pathol Res Pract       Date:  2009-10-12       Impact factor: 3.250

9.  GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis.

Authors:  R S Haber; A Rathan; K R Weiser; A Pritsker; S H Itzkowitz; C Bodian; G Slater; A Weiss; D E Burstein
Journal:  Cancer       Date:  1998-07-01       Impact factor: 6.860

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  1 in total

1.  Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response.

Authors:  Ahmed A Abdelhakeem; Xuemei Wang; Rebecca E Waters; Madhavi Patnana; Jeannelyn S Estrella; Mariela Blum Murphy; Allison M Trail; Yang Lu; Catherine E Devine; Naruhiko Ikoma; Prajnan Das; Brian D Badgwell; Jane E Rogers; Jaffer A Ajani
Journal:  Cancers (Basel)       Date:  2021-01-23       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.